Abstract
For the past century, the renin–angiotensin system (RAS) has been recognized as one of the major blood pressure-regulating systems. Angiotensin II (Ang II) is the final physiologically active product of RAS, and it works not only as a strong vasopressor but also as a promotor of tissue remodeling in various organs such as heart, arteries, and kidneys. RAS is the predominant pathway of Ang II formation in human plasma, but not in the tissues. There are several alternative pathways producing angiotensin II in human tissues, and they are involved in structural remodeling of the cardiovascular system. Proteinases such as chymase, kallikrein, cathepsin G, and elastase- 2 are probably responsible for angiotensin-converting enzyme (ACE)-independent Ang II formation in human tissues. In particular, chymase is an important Ang II-generating enzyme in the human heart. It is important to elucidate the mechanisms of the ACEindependent Ang II formation in human tissues; long-term inhibition of the local Ang II formation may become one of the strategies to prevent cardiovascular remodeling.
Keywords: Local renin–angiotensin system, angiotensin II, ACE, chymase, elastase-2, angiotensin-(1–12), cardiovascular disease.
Current Pharmaceutical Design
Title:Non-ACE Pathway-induced Angiotensin II Production
Volume: 19 Issue: 17
Author(s): Yoshinari Uehara, Shin-ichiro Miura, Eiji Yahiro and Keijiro Saku
Affiliation:
Keywords: Local renin–angiotensin system, angiotensin II, ACE, chymase, elastase-2, angiotensin-(1–12), cardiovascular disease.
Abstract: For the past century, the renin–angiotensin system (RAS) has been recognized as one of the major blood pressure-regulating systems. Angiotensin II (Ang II) is the final physiologically active product of RAS, and it works not only as a strong vasopressor but also as a promotor of tissue remodeling in various organs such as heart, arteries, and kidneys. RAS is the predominant pathway of Ang II formation in human plasma, but not in the tissues. There are several alternative pathways producing angiotensin II in human tissues, and they are involved in structural remodeling of the cardiovascular system. Proteinases such as chymase, kallikrein, cathepsin G, and elastase- 2 are probably responsible for angiotensin-converting enzyme (ACE)-independent Ang II formation in human tissues. In particular, chymase is an important Ang II-generating enzyme in the human heart. It is important to elucidate the mechanisms of the ACEindependent Ang II formation in human tissues; long-term inhibition of the local Ang II formation may become one of the strategies to prevent cardiovascular remodeling.
Export Options
About this article
Cite this article as:
Uehara Yoshinari, Miura Shin-ichiro, Yahiro Eiji and Saku Keijiro, Non-ACE Pathway-induced Angiotensin II Production, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170012
DOI https://dx.doi.org/10.2174/1381612811319170012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Nanochannel Systems for Personalized Therapy and Laboratory Diagnostics
Current Pharmaceutical Biotechnology 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology How to Investigate the Vascular Changes in Resistant Hypertension
Current Hypertension Reviews Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Epidemiology and Adverse Consequences of Hookah/Waterpipe Use: A Systematic Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Current Drug Safety Heat Shock Protein 70 kDa as a Target for Diagnostics and Therapy of Cardiovascular and Cerebrovascular Diseases
Current Pharmaceutical Design Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews A Systematic Review on Levosimendan in Paediatric Patients
Current Vascular Pharmacology Colloidal and Pharmacological Activity of Albumin in Clinical Fluid Management:Recent Developments
Current Drug Therapy Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets From Mars to Venus: Gender Differences in the Management and Outcomes of Acute Coronary Syndromes
Current Pharmaceutical Design